An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies

Area of Science:

• Oncology
• Pharmacology
• Cancer Biology

Background:

• Combination drug therapy is crucial for managing malignancies, converting monotherapies into effective treatments by targeting cancer cell dependencies.
• Identifying synergistic drug combinations is challenging due to complex tumor molecular circuitry.

Purpose of the Study:

• To develop and utilize a high-throughput platform for unbiased identification of synergistic and efficacious drug combinations.
• To discover novel drug combinations with potent antitumor activity.

Main Methods:

• A large-scale screen of 583 doublet combinations across 39 cancer cell lines using a 4x4 dosing regimen.
• Evaluation of 22,737 experiments to identify synergistic and efficacious drug pairs.
• In vitro and in vivo validation of a novel combination: Wee1 inhibitor (AZD1775) and mTOR inhibitor (ridaforolimus).

Main Results:

• Identified both known and novel synergistic and efficacious drug combinations.
• Demonstrated potent and synergistic inhibition of cancer cell growth in vitro and in vivo using the AZD1775 and ridaforolimus combination.
• The platform successfully identified combinations not easily predictable from current cancer biology understanding.

Conclusions:

• The high-throughput platform enables unbiased discovery of synergistic cancer drug combinations.
• Novel combinations, such as Wee1 and mTOR inhibitors, show significant potential for cancer therapy.
• This approach expands the predictive power beyond current knowledge of cancer cell biology.